Innovative Cellular Therapeutics
PrivateLast Round
Series C
Sep 6, 2021
Total Funding Raised
$96.9M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Innovative Cellular Therapeutics is a biotechnology company specializing in the development of chimeric antigen receptor T cell products aimed at treating blood cancers and solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Innovative Cellular Therapeutics Comparables
Compare Innovative Cellular Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Triumvira Immunologics | 85% | |
| A2 Biotherapeutics | 85% | |
| Inceptor Bio | 85% |
Innovative Cellular Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Sep 6, 2021 | ||||
| Series B Extension | Dec 18, 2019 | ||||
| Series B | Apr 24, 2018 | ||||
| Series A | Oct 1, 2016 |
Key People
Founding team and executive leadership
Innovative Cellular Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CDH Investments | Series A, Series C |
| LongHash Ventures | Series B Extension |
| Linghang Ventures | Series B Extension |
| CDH VGC | Series C |
| Shenzhen GTJA Investment Group | Series B |
| Witruth Capital | Series B |
| Volcanics Venture | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 63% MoM.
- Jul 25, 2026
Monthly visitors increased 41% to 2.1K.
Innovative Cellular Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Innovative Cellular Therapeutics's valuation, stock price, and market status.
Is Innovative Cellular Therapeutics a public or private company?
Innovative Cellular Therapeutics is a private company.
What is the current stock price of Innovative Cellular Therapeutics?
Innovative Cellular Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Innovative Cellular Therapeutics worth (valuation)?
Valuation information for Innovative Cellular Therapeutics is not publicly available.
Can I buy Innovative Cellular Therapeutics stock?
Innovative Cellular Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Innovative Cellular Therapeutics's last funding round?
Innovative Cellular Therapeutics's most recent funding round was Series C on September 6, 2021.
Who are the main investors in Innovative Cellular Therapeutics?
Key investors in Innovative Cellular Therapeutics include CDH Investments, LongHash Ventures, Shenzhen GTJA Investment Group, Volcanics Venture.
Will Innovative Cellular Therapeutics IPO soon?
No public IPO plans have been announced for Innovative Cellular Therapeutics.
How can I track Innovative Cellular Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Innovative Cellular Therapeutics's secondary market activity and sign up for updates.